Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Inclusion Criteria: * All patients must sign an informed consent indicating that they are aware of the investigational nature of this study * Patients must have histologically or cytologically confirmed low or intermediate grade neuroendocrine carcinoma, for which standard curative measures do not exist; patients with neuroendocrine tumors associated with multiple endocrine neoplasia type 1 (MEN1) syndrome will be eligible * Patients must have disease that is amenable to computed tomography (CT) or ultrasound (U/S) guided biopsies; patients must agree to undergo 2 biopsies; the disease identified for biopsy cannot be the only site of measurable disease * Patients must be registered in the M.D. Anderson Cancer Center (MDACC) institutional database prior to treatment with study drug * Zubrod performance status of 0 or 1 * Leukocytes \> 3,000/mcL * Absolute neutrophil count \> 1,500/mcL * Hemoglobin \> 9 g/dL; eligibility level for hemoglobin may be reached by transfusion * Platelets \> 100,000/mcL * Total bilirubin =\< 1.5 X upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) \< 1.5 X institutional ULN (5 x ULN if liver function tests \[LFT\] elevations due to liver metastases) * Creatinine =\< 1.5 X institutional ULN OR creatinine clearance \> 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * The p…